DCT

2:23-cv-02367

Pacira Pharma Inc v. eVenus Pharma Laboratories Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:23-cv-02367, D.N.J., 04/28/2023
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey based on Defendant eVenus being incorporated and having a regular and established place of business in the state, and Defendants' collective activities related to preparing and submitting the Abbreviated New Drug Application (ANDA) in and for the New Jersey market.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an ANDA to the FDA seeking to market a generic version of Plaintiff's EXPAREL® injectable suspension constitutes an act of infringement of a patent directed to stable, commercial-scale compositions of bupivacaine multivesicular liposomes.
  • Technical Context: The technology relates to pharmaceutical drug delivery systems, specifically extended-release local anesthetics used for post-surgical pain management as an alternative to opioids.
  • Key Procedural History: This lawsuit is a Hatch-Waxman action filed in response to Defendants' Paragraph IV certification for a newly issued patent. The complaint notes that the parties are already engaged in two prior, consolidated patent infringement suits involving the same drug product (EXPAREL®) and related patents. A claim construction (Markman) hearing was held in the consolidated cases in March 2023, but an order has not yet been issued. Plaintiff states its intent to file a motion to consolidate this new action with the prior pending cases.

Case Timeline

Date Event
2011-10-28 FDA approves commercial marketing of EXPAREL®
2021-01-22 Earliest Priority Date for U.S. Patent No. 11,426,348
2021-11-08 Plaintiff files "First Action" against eVenus and Jiangsu Hengrui
2022-02-10 Plaintiff files "Second Action" asserting an additional patent
2022-08-30 U.S. Patent No. 11,426,348 issues
2022-09-02 '348 Patent listed in FDA Orange Book
2023-03-09 Markman hearing held in prior consolidated actions
2023-04-17 Plaintiff receives Defendants' Paragraph IV Notice Letter for '348 Patent
2023-04-28 Complaint filed
2041-01-22 '348 Patent expiration date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,426,348, "Compositions of Bupivacaine Multivesicular Liposomes" (Issued Aug. 30, 2022)

The Invention Explained

  • Problem Addressed: The patent's background highlights an urgent need for new and improved large-scale manufacturing processes for EXPAREL®, an extended-release bupivacaine formulation, to meet growing market demand driven in part by the opioid epidemic '348 Patent, col. 1:39-44 The complaint elaborates that large-scale manufacturing presents complex challenges, including precise control over pH and timing-sensitive emulsion steps, where failure can lead to crystallization of the active ingredient and batch failure Compl. ¶¶12-14
  • The Patented Solution: The invention is directed to compositions of bupivacaine encapsulated in multivesicular liposomes (MVLs) that result from an improved and scaled-up commercial manufacturing process '348 Patent, abstract This scaled-up process, which involves steps like forming a water-in-oil-in-water emulsion and solvent removal, unexpectedly yields compositions with greater stability than prior methods (Compl. ¶¶7; Compl. ¶15). This enhanced stability is characterized in the patent claims by, among other things, a lower concentration of erucic acid-a lipid degradation byproduct-after the composition is stored for a period of time '348 Patent, col. 22:4-7
  • Technical Importance: By enabling the production of a more stable, extended-release local anesthetic at a commercial scale, the invention supports the wide availability of a non-opioid option for managing acute post-surgical pain Compl. ¶57

Key Claims at a Glance

  • The complaint asserts independent claims 1 (composition) and 19 (method of use), as well as dependent claims 2, 21, and 41 Compl. ¶¶62, 65-66, 85
  • Independent Claim 1 claims:
    • Batches comprising compositions of bupivacaine multivesicular liposomes (MVLs).
    • The MVLs contain bupivacaine inside internal aqueous chambers separated by lipid membranes composed of specific lipids (DEPC, DPPG) and a neutral lipid.
    • The MVLs are suspended in an aqueous medium.
    • The batches "consistently comprise an erucic acid concentration of less than about 109 µg/mL after the compositions are stored at 25°C for six months."
  • Independent Claim 19 claims:
    • A method of treating or ameliorating pain in a subject.
    • The method comprises administering a composition of claim 1 to the subject.

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are the "Proposed ANDA Products" for which Defendants seek FDA approval under ANDA No. 214348 Compl. ¶68 Compl. ¶73 These are purported generic versions of EXPAREL® (bupivacaine liposome injectable suspension) in 133 mg/10 mL and 266 mg/20 mL dosage forms Compl. ¶7

Functionality and Market Context

The accused products are injectable suspensions containing the anesthetic bupivacaine encapsulated in multivesicular liposomes (MVLs) Compl. ¶11 This structure allows for the gradual release of bupivacaine over several days to provide prolonged post-surgical pain relief Compl. ¶57 The complaint alleges that to gain FDA approval, Defendants must demonstrate that their proposed generic products are bioequivalent to Plaintiff's EXPAREL® product Compl. ¶63 The complaint includes a diagram showing the structure of an MVL particle, which consists of numerous internal chambers containing bupivacaine that are separated by lipid membranes Compl. ¶11

IV. Analysis of Infringement Allegations

'348 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
Batches comprising compositions of bupivacaine multivesicular liposomes (MVLs), The complaint alleges that Defendants' ANDA submission to make generic EXPAREL® will involve making "batches comprising compositions of bupivacaine multivesicular liposomes (MVLs)." ¶63 col. 21:58-60
(a) bupivacaine residing inside a plurality of internal aqueous chambers of the MVLs separated by lipid membranes, wherein the lipid membranes comprise 1,2,-dierucoylphosphadtidylcholine (DEPC), 1, 2-dipalmitoyl-sn-glycero-3 phospho-rac-(1-glycerol) (DPPG), and at least one neutral lipid; It is alleged that to be bioequivalent to EXPAREL®, the Defendants' proposed products must satisfy these compositional limitations. The complaint states Defendants did not dispute these limitations in a prior notice letter concerning related patents. ¶63 col. 21:61-67
(b) and an aqueous medium in which the bupivacaine encapsulated MVLs are suspended; It is alleged that the Defendants' proposed products, being injectable suspensions, will necessarily meet this limitation to achieve bioequivalence. ¶63 col. 22:1-3
(c) wherein the batches consistently comprise an erucic acid concentration of less than about 109 µg/mL after the compositions are stored at 25°C for six months. The complaint alleges the accused products will meet a narrower version of this limitation from dependent claim 2 ("less than about 99 µg/mL"), asserting this is a characteristic of scaled-up manufacturing required for bioequivalence and stability. ¶64 col. 22:4-7

Identified Points of Contention

  • Evidentiary Questions: The infringement allegation for the composition claims (e.g., Claim 1) is substantially based on the premise that for the accused product to be bioequivalent to EXPAREL®, it must inherently possess the claimed stability characteristics, such as the specified maximum erucic acid concentration after six months Compl. ¶63 Compl. ¶64 A central question for the court will be whether the evidence in the ANDA filing confirms that the defendants' specific formulation and manufacturing process will, in fact, result in a product that meets these quantitative claim limitations.
  • Scope Questions: The complaint notes that prior to the lawsuit, Defendants sought Plaintiff's interpretation of the word "consistently" as used in the claims Compl. ¶6 This raises the question of whether "consistently" requires every batch to meet the limitation, or if it implies a statistical measure of compliance across multiple batches. The resolution of this term's scope will be critical to the infringement analysis.
  • Method Claim Infringement: For the method of use claims (e.g., Claim 19), infringement will depend on whether the product label for the accused generic product instructs healthcare providers to administer the composition for treating pain Compl. ¶96 The analysis will focus on the specific language of the proposed label and whether it induces infringement by end-users.

V. Key Claim Terms for Construction

The Term: "consistently" (from claim 1)

  • Context and Importance: This term qualifies the requirement that batches comprise a certain erucic acid concentration. The complaint indicates that this term was a subject of pre-suit communications between the parties, suggesting it will be a focal point of claim construction Compl. ¶6 Practitioners may focus on this term because its definition-whether it means "invariably," "characteristically," or something else-will determine the evidentiary burden for proving infringement of the composition claims.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent does not provide an explicit definition. A party could argue that in the context of commercial-scale manufacturing, "consistently" should be understood to mean "characteristically" or "as a regular feature," allowing for some statistical process variation, as long as the batches as a whole exhibit the claimed property.
    • Evidence for a Narrower Interpretation: A party could argue that because the term is used in a patent claim, it should be given a strict meaning of "invariably" or "uniformly," meaning that infringement requires proof that every batch would meet the limitation.

The Term: "about" (e.g., "less than about 109 µg/mL" in claim 1)

  • Context and Importance: This term modifies the numerical limits of the claims and is critical for determining the boundary between literal infringement and non-infringement. Practitioners may focus on this term because the degree of numerical flexibility it affords could be outcome-determinative if the accused product's measured properties are close to the specified thresholds.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The repeated use of "about" with various parameters throughout the patent (e.g., "about 5.50" for pH, "about 0.03 mg/mL" for lysine concentration) suggests a general intention to avoid sharp numerical boundaries '348 Patent, col. 18:37 '348 Patent, col. 18:41
    • Evidence for a Narrower Interpretation: The specification provides specific data points with one or two decimal places of precision (e.g., Table 1A shows erucic acid concentrations like 22.7 and 98.7 µg/mL) '348 Patent, col. 21:Table 1A A party may argue that this level of precision implies that "about" should be construed narrowly to encompass only minor variations consistent with measurement error.

VI. Other Allegations

Indirect Infringement

The complaint alleges both induced and contributory infringement.

  • Induced Infringement (35 U.S.C. § 271(b)): Plaintiff alleges that Defendants know of the '348 patent and that the labeling for the proposed generic products will instruct healthcare providers to administer the product to treat pain, which will actively induce infringement of method claims 19 and 21 Compl. ¶¶76, 96, 100
  • Contributory Infringement (35 U.S.C. § 271(c)): The complaint alleges that the accused products are especially made and adapted for infringing the patent, are a material part of the invention, and are not staple articles of commerce suitable for substantial non-infringing use Compl. ¶¶77, 113-114

Willful Infringement

Willfulness allegations are based on Defendants' alleged knowledge of the '348 patent, purportedly gained no later than its issuance and listing in the FDA's Orange Book, and as evidenced by their service of a Paragraph IV Notice Letter Compl. ¶75 Compl. ¶92 For the method claims, the complaint alleges Defendants were willfully blind to infringement because their proposed product labeling provides instructions for the patented use Compl. ¶99

VII. Analyst's Conclusion: Key Questions for the Case

  • Evidentiary Link: A central issue will be evidentiary: does the data within Defendants' ANDA, submitted to prove bioequivalence to EXPAREL®, also conclusively demonstrate that the proposed generic product will meet the specific quantitative limitations of the asserted composition claims, particularly the erucic acid stability marker claimed in U.S. Patent No. 11,426,348?
  • Definitional Scope: The case may turn on a core claim construction dispute over the term "consistently." The court's interpretation of whether this term requires every single manufactured batch to meet the claim's stability requirement, or whether it allows for a statistical average or typical performance, will fundamentally shape the infringement analysis.
  • Induced Infringement via Labeling: For the asserted method-of-use claims, a key question will be whether the specific instructions for use in the final, FDA-approved label for Defendants' product will direct healthcare providers to perform actions that fall within the scope of the patented methods, thereby establishing the intent required for induced infringement.
Loading Complaint